 which is incredibly important. We have over 30 bills that are Komen-led bills in the docket right now. And then we also have cutting edge research. And I will tell you that the research that we do is second to none and pretty incredible. And one of the things that I'm most proud of is our Share for Cures platform. And that's a brainchild that we created about three, four years ago now and built